Gene Transfer Treatment of Articular Cartilage Damage

  • Trippel, Stephen, (PI)

Project: Research project

Description

DESCRIPTION (provided by applicant): Growth factor gene transfer to articular chondrocytes may be capable of augmenting cell-based approaches to articular cartilage repair. Currently available data is insufficient to enable translation into clinical use. The purpose of this proposal is to help close the gap between present mechanistic knowledge and therapeutic application. We will focus on three related specific aims. Aim 1: Define a potentially therapeutic set of growth factor genes for articular cartilage repair by determining how interactions among selected growth factors regulate articular chondrocyte function. Hypothesis 1: IGF-I, FGF-2, BMP-2, and BMP-7, when employed for articular chondrcyte gene transfer, interact to differentially regulate the expression of genes that influence chondrocyte reparative functions. Aim 2: Determine whether genetic and tissue engineering methods, when applied to articular chondrocytes, are interdependent. Hypothesis 2: Chemically distinct biomaterials, including alginate, collagen, and hyaluronic acid-based gels, differentially modulate the effects of growth factor gene transfer. Aim 3: Determine whether transfer of an optimized set of growth factor genes coupled with an optimized biomaterial can generate durable repair in a large animal model of cartilage loss. Hypothesis 3: Optimal repair of articular cartilage lesions requires a modulation of cell proliferation and matrix synthesis. Articular chondrocytes treated by gene transfer with selected combinations of growth factors and delivered in a selected hydrogel differentially promote repair of intrachondral articular cartilage defects in the equine knee. The demonstration that interactions between these genetic engineering and tissue engineering technologies promote repair by articular chondrocytes would lend insight into the mechanisms that regulate cell-based therapies and provide a key step in the translation of these therapies to human articular cartilage diseases. PUBLIC HEALTH RELEVANCE: Articular cartilage damage is the cause of pain and disability from acute joint trauma and chronic joint arthritis, and remains an unsolved problem in modern orthopaedics. Current therapies can help the symptoms that result from cartilage loss, but treatments are lacking that can correct the cartilage loss itself. This is a translational research project that will combine gene therapy and tissue engineering methods in a pre-clinical model to test a potential new treatment approach to articular cartilage repair.
StatusFinished
Effective start/end date4/1/012/29/16

Funding

  • National Institutes of Health: $469,014.00
  • National Institutes of Health: $320,446.00
  • National Institutes of Health: $394,491.00
  • National Institutes of Health: $472,077.00
  • National Institutes of Health: $398,475.00
  • National Institutes of Health: $320,446.00
  • National Institutes of Health: $294,879.00
  • National Institutes of Health: $551,820.00
  • National Institutes of Health: $332,314.00
  • National Institutes of Health: $286,327.00

Fingerprint

Articular Cartilage
Intercellular Signaling Peptides and Proteins
Chondrocytes
Cartilage
Joints
Genes
Dependovirus
Tissue Engineering
Genetic Engineering
Biocompatible Materials
Fibroblast Growth Factor 2
Insulin-Like Growth Factor I
Therapeutics
Cartilage Diseases
Bone Morphogenetic Protein 7
Orthopedics
IGF Type 1 Receptor
Growth Factor Receptors
Hydrogel
Hyaluronic Acid

ASJC

  • Medicine(all)